Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 939-949

  Cai, Ke Xia ^a   Lai, Ying Tse ^b   Leung, Carly ^a   Tam, Paul K H ^a   Xu, Ruian ^b,c   Mai, Har Sham ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c HUAQIAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CALRETICULIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VASOSTATIN;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOCOMPETENCE; LUNG METASTASIS; LUNG TUMOR; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME; VALIDATION PROCESS; XENOGRAFT;

EID: 39049165759     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1930     Document Type: Article

References (46)

1. Cao Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int J Biochem Cell Biol 2001;33:357-69.
2. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27.
3. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003;21:223-31.
4. Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004;114:898-907.
5. Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 1998;188:2349-56.
6. Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 1999;94:2461-8.
7. Xiao F, Wei Y, Yang L, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 2002;9:1207-13.
8. Li L, Yuan YZ, Lu J, et al. Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice. Gut 2006;55:259-65.
9. Lange-asschenfeidt B, Velasco P, Streit M, et al. The angiogenesis inhibitor vasostatin doses not impair wound healing at tumor-inhibiting dose. J Invest Dermatol 2002;53:154.
10. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-57.
11. Kuo C J, Farnebo F, Yu EY, et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proc Natl Acad Sci USA 2001;98:4605-10.
12. Aitken ML, Moss RB, Waltz DA, et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. Hum Gene Ther 2001;12:1907-16.
13. Arruda VR, Fields PA, Milner R, et al. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 2001;4:586-92.
14. Jiang H, Lillicrap D, Patarroyo-White S, et al. Multi-year therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 2006;108:107-15.
15. Davidoff AM, Nathwani AC, Spurbeck WW, et al. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 2002;62:3077-83.
16. Xu R, Sun X, Tse LY, et al. Long-term expression of angiostatin suppresses metastatic liver cancer inmice. Hepatology 2003;37:1451-60.
17. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004;64:1781-7.
18. Zabner J, Seiler M, Walters R, et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000;74:3852- 8.
19. Auricchio A, O'Connor E, Weiner D, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002;110:499-504.
20. Xu R, Janson CG, Mastakov M, et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes. Gene Ther 2001;8:1323-32.
21. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72:2224-32.
22. Sun X, Krissansen GW, Fung PW, et al. Anti-angiogenic therapy subsequent toad eno-associated-virus-mediated immunotherapy eradicates lymphomas that disseminate to the liver. Int J Cancer 2005;113:670-7.
23. Doki Y, Murakami K, Yamaura T, et al. Mediastinal lymph node metastasis model by orthotopic intrapulmonary implantation of Lewis lung carcinoma cells in mice. Br J Cancer 1999;79:1121-6.
24. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
25. Hirata T, Fukuse T, Naiki H, Wada H. Expression of E-cadherin and lymph node metastasis in resected non-small-cell lung cancer. Clin Lung Cancer 2001;3:134-40.
26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
27. Shi J, Zheng D, Liu Y, et al. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Cancer Res 2005;65:1687-92.
28. Isayeva T, Chanda D, Kallman L, Eltoum IE, Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 2007;67:5789-97.
29. Hirschi KK, Rohovsky SA, D'Amore PA. PDGF,TGF-β, and heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 1998;141:805-14.
30. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653-60.
31. Bunn PA, Jr., Chan DC, Earle K, et al. Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer. Semin Oncol 2002;29:87-94.
32. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-85.
33. Mathieu A, Remmelink M, D'Haene N, et al. Development of a chemoresistant orthotopic human non-small cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-a (GST)-α, GST-mu, and GST-pi. Cancer 2004;101:1908-18.
34. Oga M, Takenaga K, Sato Y, et al. Inhibition of metastatic brain tumor growth by intramuscular administration of the endostatin gene. Int J Oncol 2003;23:73-9.
35. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
36. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor β-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation toa ngiogenesis. Cancer Res 1997;57:963-9.
37. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
38. Li TS, Kaneda Y, Ueda K, et al. The influence of tumour resection on angiostatin levels and tumour growth-an experimental study in tumour-bearing mice. Eur J Cancer 2001;37:2283-8.
39. Maniwa Y, Okada M, Ishii N, Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114:1668-75.
40. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
41. Gorski DH, Mauceri HJ, Salloum RM, et al. Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res 2003;63:308-11.
42. Camphausen K, Moses MA, Beecken WD, et al. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-11.
43. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res 2001;7:3366-74.
44. Ma HI, Guo P, Li J, et al. Suppression of intracranial human glioma growth after intramuscular administration of an adeno-associated viral vector expressing angiostatin. Cancer Res 2002;62:756-63.
45. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998;101:1055-63.
46. Virella-Lowell I, Zusman B, Foust K, et al. Enhancing rAAV vector expression in the lung. J Gene Med 2005;7:842-50.